<a href="https://www.fiercebiotech.com/biotech/takedas-tyk2-inhibitor-beats-bristol-myers-sotyktu-psoriasis-showdown" hreflang="en">Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown</a>
Takeda's TYK2 inhibitor, zasocitinib, has outperformed Bristol Myers Squibb’s Sotyktu in a phase 3 trial for treating moderate-to-severe plaque psoriasis, achieving over 35% complete skin clearance compared to Sotyktu's 14%. This success positions Takeda favorably ahead of its planned launch of zasocitinib in early 2027.
Takeda's successful phase 3 trial results for its TYK2 inhibitor zasocitinib, which showed significant superiority over Bristol Myers Squibb's Sotyktu in treating moderate-to-severe plaque psoriasis, highlight a strong investment opportunity in their upcoming launch, anticipated for the first half of 2027. This positions Takeda as a formidable competitor in the psoriasis treatment market, especially considering the high efficacy and safety profile demonstrated in the trials. For a professional tracking healthtech and biotech, this development signals a potential shift in market dynamics and could influence strategic decisions or investments in psoriasis therapeutics.